Rheumnow

Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?  

Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com

Join rheumatology experts Dr. John J. Cush and Dr. Arthur Kavanaugh for the EULAR Rheumatology RoundUp — a dynamic, fast-paced discussion capturing the most impactful highlights, late-breaking data, and clinical takeaways from EULAR 2025.

Trends and Innovations from Barcelona (6.20.2025) AI Advances axSpA Diagnosis with Multimodal MRI IL-17 Inhibitors in Psoriatic Arthritis IL-17 Inhibitors for Axial Spondyloarthritis New IL-17 Inhibition New Molecular Constructs

Resilience or Resignation? Rethinking Pain, Aging, and Quality of Life Spondyloarthritis Panel: Eular 2025

Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what’s new from EULAR 2025 and what it means for improving patient outcomes.

Digital Behavioural Therapy for Persistent Pain in Axial Spondyloarthritis There's an App for That (and it works): the AXIA RCT

Eular 2025 PsA Topic Panel Assessment of Peripheral Arthritis in Spondyloarthritis IL-17 inhibitors - Novel Drugs IL17 inhibitors - Long-term Extensions and Uveitis IL17 inhibitors - STAMP T2T and Combinations Using AI for Reading PET/CT in Rheumatoid Arthritis

Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don’t miss this in-depth panel as they unpack key findings from EULAR 2025 and discuss what’s next for RA care.

Efficacy and Safety of Xeligekimab in AS Sonelokimab in PsA Seronegative Arthritis Breakthroughs Novel Therapies in Axial Spondyloarthritis

JAK Inhibitors: The Latest from the JAK-pot Study Does Abatacept Buy You Time Off RA? How to Properly Use Steroids in Early RA: Oral vs Parenteral All Rheumatoid Arthritis is Not the Same Jekyll and Hyde: which RA-ILD is it? RA treatment: A Constant State of Evolution

Who/When to Treat Clinically Suspect Arthralgia Thoughtful, Effective RA Care Should be Guided by Need —Not Age The Impact of Biologics on Methotrexate Adherence Jokes Aside: The Impact of Laughter in RA JAK Safety Update Why is RA Difficult to Treat? DMARD Combinations in RA Treatment Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data ALTO: Long-term Outcomes of APIPPRA

Efficacy and Safety of Xeligekimab in AS Lessons on Uveitis and AxSpA Difficult to Treat Axial Spondyloarthritis MRI Lesions in Early axSpA vs Non-axSpA Emerging Therapies in Axial Spondyloarthritis Chronic Pain in AxSpA Beyond Fibromyalgia Novel Therapies in Axial Spondyloarthritis GLP 1 Receptor Agonists in axSpA Patients

Difficult to Treat Psoriatic Arthritis Less or more frequent dosing in PsA? Complex-to-Manage PsA: The GRAPPA Framework and Definition Biologic Switching in PsA Decoding Difficult to Treat PsA Deucravacitinib in Psoriatic Arthritis: A New Oral Option with Dual Impact

EULAR 2025 - Day 1 podcasts Sonelokimab in PsA Seronegative Arthritis Breakthroughs Using Combination csDMARDs in PsA Deucravacitinib's Place in the PsA Treatment Algorithm?

Biologic Switching in PsA Decoding Difficult to Treat PsA Deucravacitinib in Psoriatic Arthritis: A New Oral Option with Dual Impact GLP 1 Receptor Agonists in axSpA Patients Jekyll and Hyde: which RA-ILD is it? RA treatment: A Constant State of Evolution

Difficult to Treat Psoriatic Arthritis Less or more frequent dosing in PsA? Complex-to-Manage PsA: The GRAPPA Framework and Definition Emerging Therapies in Axial Spondyloarthritis Chronic Pain in AxSpA Beyond Fibromyalgia Novel Therapies in Axial Spondyloarthritis JAK Inhibitors: The Latest from the JAK-pot Study Does Abatacept Buy You Time Off RA? How to Properly Use Steroids in Early RA: Oral vs Parenteral All Rheumatoid Arthritis is Not the Same

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the fourth day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.